Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Updates on financing discussions and current financial position. Signs non-binding term sheet with a third-party investor. Investor is expected to provide funding of up to $80 million to meet the company’s cashflow requirements through to the European certification of the LIGHT System. Notes the treatment of first patients with LIGHT is now targeted for 2024 with certification of the LIGHT System to follow thereafter. Anticipates the financing to be a mixture of equity and debt financing.

Company also says talks on bridge financing are ongoing and has raised £200,000 via a short-term four-month unsecured loan agreement with a new investor, and raised £150,000 from an existing investor under its secured convertible loan note agreement.

Current stock price: suspended at 1.75 pence

12-month change: down sharply from 1,925p

Copyright 2023 Alliance News Ltd. All Rights Reserved.